Pharmacists need to brush up on their knowledge of the interchangeable biosimilar designation, investigators said in a survey presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting.
Pharmacists have limited awareness of concepts underlying FDA approval of the interchangeable designation for biosimilars, according to survey findings presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021 meeting.
Just 20% correctly answered that based on FDA approval of interchangeable status, a pharmacist can substitute a biosimilar for a reference drug without consulting with the prescribing physician.
Slightly more than half (53%) correctly answered that it is “appropriate for a pharmacist to dispense an interchangeable biosimilar in place of its reference product without authorization from the prescriber if consistent with state law.”
Community pharmacists (50%) were less likely to answer this question correctly than those in other practice settings (54%-61%).
“Additional and focused educational strategies for US pharmacists are required to bridge these gaps and increase confidence in dispensing biosimilars,” authors of the study concluded.
States do have ultimate say in allowing biosimilars to be used interchangeably, although the FDA is the granting authority when it comes to approving biosimilars as interchangeable with their reference products. There are 2 approved interchangeable biosimilars: Semglee (insulin glargine) and Cyltezo (adalimumab). Only Semglee is on the market currently.
All states have passed laws governing how interchangeable biosimilars may be dispensed. Cardinal Health has documented these in an extensive state-by-state user guide.
The survey was conducted in March 2021, prior to when the first US interchangeable biosimilar was approved (July 2021), and pharmacist respondents were relatively unaware that no biosimilars had been designated as interchangeable when they answered the questionnaire. Just 11% answered correctly that all of 12 biosimilars on a list were not interchangeable. “Awareness was slightly higher among managed care pharmacists in other practice settings,” the authors wrote.
In the survey findings, which were presented at the AMCP Nexus 2021 meeting, investigators described the increasing relevance of biosimilars and interchangeable biosimilars to the practice of pharmacy.
“The potential to deliver cost savings may increase patient access to biologic therapies and help control overall health care costs,” they wrote.
In conducting the survey, they sought to plug gaps in available quantitative data on US pharmacists’ attitudes toward and understanding of biosimilars. Investigators derived their data from 500 survey forms (curated from 992 individual responses) representative of the Northeast, South, Midwest, and West.
The survey consisted of 36 questions that assessed biosimilar knowledge and understanding from FDA approval to state pharmacy law and patient involvement.
Investigators said 81% of respondents correctly answered that a biosimilar approved for all the same indications of the reference product is not automatically interchangeable with that product.
Hospital or health system pharmacists got this question right (71%) less often than those in other practice settings (81%-96%), and investigators said it was probably because the general use of “therapeutic equivalence” in health care systems can be confusing.
They said 83% correctly responded that an interchangeable biosimilar is not the same thing as a generic drug.
A higher percentage (86%) correctly answered that switching studies are required for a biosimilar to demonstrate interchangeability and involve multiple switches from reference drug to biosimilar.
They said 16% answered incorrectly that all biosimilars are approved as being interchangeable.
Most pharmacists answered correctly (87%) that noninterchangeable biosimilars are as safe and effective as interchangeable biosimilars.
Just 51% of pharmacists said they were at least moderately comfortable answering patients’ questions about biosimilars, and 29% said they were “somewhat” comfortable.
Just 36% of pharmacists said they always or mostly involve patients in decisions about starting therapy with a biosimilar and switching to a biosimilar, whereas 32% said they “sometimes” do.
Investigators said 66% of the respondents worked in a community setting. The remainder were evenly split among home care or home infusion settings, ambulatory or outpatient centers, or specialty pharmacy and hospital/health system environments. A smaller percentage, 5%, worked in a managed care setting.
Investigators said 32% had practiced pharmacy for more than 20 years and 37% for 10 years or fewer.
“The majority of respondents correctly stated that a biosimilar has equivalent efficacy (87%) and comparable safety (91%) to its reference product,” they wrote.
The pharmacists were better versed in state laws on pharmacy and “correctly answered further questions on state pharmacy laws and biosimilar substitution,” the report said.
Reference
Stevenson JG, McCabe D, McGrath M, McBride A. A survey to assess pharmacists’ knowledge and understanding of biosimilars and interchangeability. Poster presented at: AMCP Nexus 2021; October 18-21, 2021.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.